JP2013521312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013521312A5 JP2013521312A5 JP2012556283A JP2012556283A JP2013521312A5 JP 2013521312 A5 JP2013521312 A5 JP 2013521312A5 JP 2012556283 A JP2012556283 A JP 2012556283A JP 2012556283 A JP2012556283 A JP 2012556283A JP 2013521312 A5 JP2013521312 A5 JP 2013521312A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- membered
- sulfur
- oxygen
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 23
- 229910052757 nitrogen Inorganic materials 0.000 claims 17
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 239000001301 oxygen Substances 0.000 claims 15
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 239000011593 sulfur Substances 0.000 claims 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 229920006395 saturated elastomer Polymers 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 claims 1
- 102100029095 Exportin-1 Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims 1
- 101150094313 XPO1 gene Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 108700002148 exportin 1 Proteins 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000008467 tissue growth Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 *OC(CC[n](cn1)nc1I)=O Chemical compound *OC(CC[n](cn1)nc1I)=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31081010P | 2010-03-05 | 2010-03-05 | |
| US61/310,810 | 2010-03-05 | ||
| US38327510P | 2010-09-15 | 2010-09-15 | |
| US61/383,275 | 2010-09-15 | ||
| PCT/US2011/027328 WO2011109799A1 (en) | 2010-03-05 | 2011-03-05 | Nuclear transport modulatiors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013521312A JP2013521312A (ja) | 2013-06-10 |
| JP2013521312A5 true JP2013521312A5 (enExample) | 2014-04-17 |
| JP5816635B2 JP5816635B2 (ja) | 2015-11-18 |
Family
ID=44542615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556283A Active JP5816635B2 (ja) | 2010-03-05 | 2011-03-05 | 核輸送調節剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8513230B2 (enExample) |
| EP (1) | EP2542089B1 (enExample) |
| JP (1) | JP5816635B2 (enExample) |
| CN (1) | CN103002742B (enExample) |
| AU (1) | AU2011222531B2 (enExample) |
| CA (1) | CA2791914C (enExample) |
| WO (1) | WO2011109799A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| JP6106605B2 (ja) | 2011-01-17 | 2017-04-05 | カリオファーム セラピューティクス，インコーポレイテッド | オレフィン含有核輸送調節剤およびその使用 |
| CA2842364A1 (en) * | 2011-07-29 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| ES2954991T3 (es) * | 2011-07-29 | 2023-11-28 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear que contienen hidrazida y usos de los mismos |
| SG11201401531RA (en) | 2011-11-11 | 2014-07-30 | Pfizer | 2-thiopyrimidinones |
| SMT202000347T1 (it) * | 2012-05-09 | 2020-07-08 | Biogen Ma Inc | Modulatori di trasporto nucleare e loro usi |
| CA2880896C (en) | 2012-06-26 | 2021-11-16 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN103937872A (zh) * | 2013-01-23 | 2014-07-23 | 上海市东方医院 | Crm1在胃癌诊断与治疗中的应用 |
| WO2014144772A1 (en) * | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| WO2014152263A1 (en) * | 2013-03-15 | 2014-09-25 | Karyopharm Therapeutics Inc. | Exo olefin-containing nuclear transport modulators and uses thereof |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| PL3010892T3 (pl) | 2013-06-21 | 2019-07-31 | Karyopharm Therapeutics, Inc. | 1,2,4-triazole jako modulatory transportu jądrowego i ich zastosowania |
| WO2014205393A1 (en) * | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2015079031A1 (en) * | 2013-11-28 | 2015-06-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of beta-thalassemias |
| CN111484483B (zh) | 2014-08-15 | 2023-05-26 | 卡尔约药物治疗公司 | 赛灵克斯的多晶型物 |
| EP3265445B1 (en) | 2015-03-06 | 2021-05-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| BR112017019150B1 (pt) | 2015-03-06 | 2023-05-09 | Pharmakea, Inc | Compostos inibidores de lisil oxidase-like 2 fluorados, composição farmacêutica e uso desses compostos |
| BR112017022340A2 (pt) | 2015-05-05 | 2018-07-10 | Pfizer | 2-tiopirimidinonas |
| WO2017050969A1 (en) * | 2015-09-24 | 2017-03-30 | Universite Paris Est Creteil Val De Marne | Heterocyclic ho-1 inducers, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation |
| WO2017091513A1 (en) * | 2015-11-24 | 2017-06-01 | Daiichi Sankyo Company, Limited | Novel azole derivatives as apelin receptor agonist |
| EP3397634A1 (en) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| EP3397633A1 (en) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| WO2017136453A1 (en) * | 2016-02-03 | 2017-08-10 | Rigel Pharmaceuticals, Inc. | Nrf2 activating compounds and uses thereof |
| HUE052269T2 (hu) | 2016-02-03 | 2021-04-28 | Rigel Pharmaceuticals Inc | NRF2-t aktiváló vegyületek és alkalmazásuk |
| JP7079772B2 (ja) | 2016-09-07 | 2022-06-02 | ファーマケア，インク． | リシルオキシダーゼ様２阻害剤の結晶形態および製造方法 |
| KR102615565B1 (ko) | 2016-09-07 | 2023-12-18 | 파마케아, 인크. | 리실 옥시다제 유사 2 억제제의 용도 |
| WO2018050801A1 (en) | 2016-09-16 | 2018-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| CN106831617A (zh) * | 2017-01-17 | 2017-06-13 | 广州市闻皓生物科技有限公司 | 一种Selinexor中间体的合成工艺 |
| US10899745B2 (en) | 2017-03-30 | 2021-01-26 | Bristol-Myers Squibb Company | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide |
| JP7167168B2 (ja) | 2018-01-10 | 2022-11-08 | エックスダブリューファルマ リミテッド | ケタミンのプロドラッグ、組成物及びそれらの使用 |
| WO2019232724A1 (en) | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
| CA3135712A1 (en) | 2019-05-01 | 2020-11-05 | Brian Clinton AUSTAD | Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors |
| EP3968987A4 (en) * | 2019-05-16 | 2022-10-26 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| EP4106876B1 (en) | 2020-02-18 | 2025-09-17 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2022089629A1 (zh) * | 2020-11-02 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | 1,2,4-三氮唑衍生物及其制备方法和用途 |
| WO2022143779A1 (zh) * | 2020-12-29 | 2022-07-07 | 南京明德新药研发有限公司 | 含烯基类化合物及其应用 |
| CN113045550A (zh) * | 2021-03-12 | 2021-06-29 | 深圳济康医药科技有限公司 | 一种三氮唑类衍生物及其制备方法和应用 |
| KR102923359B1 (ko) | 2021-04-16 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| CN113292444A (zh) * | 2021-06-02 | 2021-08-24 | 陕西中医药大学 | 含有多取代基的联稀酰胺化合物及其制备方法 |
| AU2022326513B9 (en) | 2021-08-13 | 2025-10-23 | XWPharma Ltd. | Pharmaceutical compositions and oral dosage forms of ketamine derivatives |
| EP4387977A1 (en) | 2021-08-18 | 2024-06-26 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| CN115925682B (zh) * | 2021-10-04 | 2025-11-25 | 山东新时代药业有限公司 | 一种托匹司他的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL97249A (en) | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| EP1360901A1 (en) | 1996-04-25 | 2003-11-12 | Nissan Chemical Industries, Limited | 2,3-cyclic substituted derivatives of 3-hydroxyacrolein and 3-hydroxyacrylic acid as pesticides |
| US8637559B2 (en) * | 2005-11-15 | 2014-01-28 | Otsuka Pharmaceutical Co., Ltd. | Oxazole compound and pharmaceutical composition |
| PL1992618T3 (pl) | 2006-03-09 | 2012-06-29 | Eisai R&D Man Co Ltd | Policykliczna pochodna cynamidowa |
| NZ572268A (en) * | 2006-04-18 | 2011-09-30 | Nippon Chemiphar Co | Activating agent for peroxisome proliferator activated receptor delta (ppar) |
| JP4999923B2 (ja) | 2006-06-13 | 2012-08-15 | 中国科学院上海薬物研究所 | 複素環非ヌクレオシド系化合物、抗ウィルス医薬組成物、及びウィルス性疾病治療薬物 |
| JP4388997B2 (ja) | 2006-09-05 | 2009-12-24 | 協和発酵キリン株式会社 | イミダゾール誘導体 |
| EP1939180A1 (en) * | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| JP6106605B2 (ja) | 2011-01-17 | 2017-04-05 | カリオファーム セラピューティクス，インコーポレイテッド | オレフィン含有核輸送調節剤およびその使用 |
| ES2954991T3 (es) | 2011-07-29 | 2023-11-28 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear que contienen hidrazida y usos de los mismos |
| CA2842364A1 (en) | 2011-07-29 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| SMT202000347T1 (it) | 2012-05-09 | 2020-07-08 | Biogen Ma Inc | Modulatori di trasporto nucleare e loro usi |
| WO2014144772A1 (en) | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| WO2014152263A1 (en) | 2013-03-15 | 2014-09-25 | Karyopharm Therapeutics Inc. | Exo olefin-containing nuclear transport modulators and uses thereof |
| WO2014205393A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| PL3010892T3 (pl) | 2013-06-21 | 2019-07-31 | Karyopharm Therapeutics, Inc. | 1,2,4-triazole jako modulatory transportu jądrowego i ich zastosowania |
-
2011
- 2011-03-05 CN CN201180022653.4A patent/CN103002742B/zh active Active
- 2011-03-05 WO PCT/US2011/027328 patent/WO2011109799A1/en not_active Ceased
- 2011-03-05 US US13/041,377 patent/US8513230B2/en active Active
- 2011-03-05 EP EP11751491.9A patent/EP2542089B1/en active Active
- 2011-03-05 CA CA2791914A patent/CA2791914C/en active Active
- 2011-03-05 JP JP2012556283A patent/JP5816635B2/ja active Active
- 2011-03-05 AU AU2011222531A patent/AU2011222531B2/en active Active
-
2013
- 2013-06-28 US US13/931,372 patent/US9550757B2/en active Active